Search Results
May 15, 2026, 17:00 ET TuHURA Biosciences Reports First Quarter 2026 Financial Results and Provides a Corporate Update
dose limiting toxicities. Additionally, the study demonstrated that patients refractory to checkpoint inhibitor therapy (anti-PD1) experienced clinical benefit upon subsequent anti-PD1 based treatment.Anticipated Milestones by ProgramIFx-2.0 (Innate Immune Agonist)
More news about: TuHURA Biosciences, Inc.
May 15, 2026, 07:36 ET Keenova Announces Newly Updated Peyronie's Disease Study Results at American Urology Association Meeting
Peyronie's DiseasePeyronie's disease (PD) is a condition in which a buildup of fibrous scar tissue causes a curvature deformity of the penis. This curvature can be bothersome during arousal and intimacy.1 It is estimated that PD can affect as many as 1 in 10 men in the U.S.,2* but
More news about: Keenova Therapeutics
May 14, 2026, 19:03 ET SN BioScience Doses First Patient in Phase 1b/2 Clinical Trial of 'SNB-101'
monotherapy program, SN BioScience is actively expanding the development of SNB-101 into combination strategies with immunotherapy agents (including anti-PD-1, anti-PD-L1, and DLL3-targeted BiTE® T-cell engager therapies) currently used in standard SCLC treatment. The company has already obtained EMA approval
More news about: SN BioScience Inc
May 14, 2026, 16:02 ET Inhibrx Reports First Quarter 2026 Financial Results
combination with pembrolizumab (the combination arm) versus pembrolizumab monotherapy (the control arm) in first-line patients with treatment-naïve, PD-L1 positive (Combined Positive Score (CPS) ≥ 20) metastatic or unresectable recurrent Head and Neck Squamous Cell Carcinoma (HNSCC).We plan
More news about: Inhibrx Biosciences, Inc.
May 14, 2026, 12:48 ET Kansas City Deploys Regional Drone Security and Airspace Coordination Platform for FIFA World Cup 2026
multi-agency and multi-jurisdictional coordination between KCPD, Kansas City Missouri Police and Fire Departments, Shawnee PD, Overland Park PD, Prairie Village PD, Kansas City Kansas PD, Lawrence PD, Kansas Highway Patrol, Johnson County Sheriff's Office, Sporting Kansas City, and additional regional stakeholders
More news about: Airspace Link
May 13, 2026, 16:05 ET INOVIO Reports First Quarter 2026 Financial Results and Recent Business Highlights
supply agreement with Akeso Inc. to evaluate INO-5412 (INO-5401 plus INO-9012 in a single vial) in combination with cadonilimab, Akeso's first-in-class PD-1/CTLA-4 bispecific antibody, for the potential treatment of glioblastoma (GBM). The combination therapy will be studied as a part of the INdividualized
More news about: INOVIO Pharmaceuticals, Inc.
May 13, 2026, 11:19 ET The 5 Strategic Projects Quietly Defining the Next Decade of West's Critical Minerals Supply
25.4 Moz palladium-equivalent and 23.5 Moz gold-equivalent across the combined Indicated and Inferred categories — one of the largest undeveloped Pd-Au-Pt deposits on Earth, with a gross undiscounted in-situ resource value of approximately $68 billion at February 2026 metal prices, calculated on an
More news about: American News Group
May 13, 2026, 10:05 ET Creatv Bio Opens CLIA-Certified Laboratory to Support Oncology Drug Development
downregulation and resistance to therapies.Measures PD-L1 Expression for Immunotherapy – Creatv offers the first blood test for detecting PD-L1 expression changes in patients and their subsequent response to PD-L1/PD-1 checkpoint inhibitors."The opening of our
More news about: Creatv MicroTech, Inc.
May 13, 2026, 10:00 ET Sony Electronics Accelerates High-Resolution Photography with the Alpha 7R VI
occurred at the microphone input stage, it cannot be restored even if the volume is adjusted in post-production.[15] A USB Power Delivery (PD)-compatible external power supply and USB cable are not included.
More news about: Sony Electronics, Inc.
May 13, 2026, 08:30 ET Greenland Mines Ltd to Present at CMI Summit 5 as Western-Aligned PGM and Critical Minerals Developer
converted to Mineral Reserves or that an economically viable mining operation can be established.¹ Based on cumulative contained ounces of Au, Pd, and Pt in the 2022 NI 43-101 Technical Report MRE and February 2026 metal prices. Gross in-situ contained metal value only; excludes all mining, processing,
More news about: Greenland Mines Ltd
May 13, 2026, 08:30 ET Newmont Transaction Highlights Rising Valuations For Undeveloped Gold Assets
prices[3]. Greenland Mines holds an 80% direct interest in the Project and an option on the remaining 20%.The 2022 base case used $1,725/oz Pd, $1,800/oz Au, and $1,250/oz Pt. SLR's three sensitivity scenarios — Low, Medium, and High — applied updated metal price assumptions ranging from $3,000/oz
More news about: Baystreet
May 12, 2026, 20:00 ET Kelun-Biotech Receives Investigational New Drug Approval from CDE for SKB118, a PD-1 x VEGF Bispecific Antibody
antibody being developed for the treatment of solid tumors that combines two complementary, validated mechanisms in oncology via a blockade of PD-1 and VEGF. PD-1 checkpoint inhibition is aimed at restoring T cells' ability to recognize and destroy tumor cells, and blocking VEGF is intended to reduce blood
More news about: Kelun-Biotech
May 12, 2026, 20:00 ET 科倫博泰PD-1 x VEGF雙抗SKB118新藥臨床試驗申請獲CDE批准
）SKB118是一款四價雙特異性抗體，目前正開發用於治療實體瘤。其結合了腫瘤學中兩種互補且經過驗證的作用機制——PD-1和VEGF阻斷，其中對PD-1檢查點的抑制可恢復T細胞識別和摧毀腫瘤細胞的能力，而VEGF阻斷可減少對腫瘤細胞的血液供應並抑制腫瘤生長。在臨床前研究中，SKB118在VEGF存在的情況下顯示出提升PD-1的結合和信號阻斷能力的協同藥理作用，並具有強大的抗腫瘤活性。SKB118的抗VEGF活性還可能使腫瘤部位的血管正常化，有望提高聯合療法(例如與抗體偶聯藥物(ADC)聯用)在腫瘤局部的富集與療效。關於科倫博泰四川科倫博泰生物醫藥股份有限公司(簡稱
More news about: 科倫博泰
May 12, 2026, 17:15 ET Franco-Nevada Reports Record Q1 2026 Results
Our 2026 guidance assumes the following commodity prices: $4,500/oz Au, $75.00/oz Ag, $2,000/oz Pt, $1,650/oz Pd, $100/tonne Fe 62% CFR China, $70/bbl WTI oil and $3.00/mcf Henry Hub natural gas. GEOs for the 2026 period are calculated based on fixed conversion ratios
More news about: Franco-Nevada Corporation
May 12, 2026, 16:00 ET Curis Provides First Quarter 2026 Business Update
treated with emavusertib in combination with FOLFOX and anti-PD1 +/- trastuzumab as first-line therapy for metastatic or unresectable gastroesophageal cancers. The poster titled A phase I trial of emavusertib (CA-4948) in combination with FOLFOX/ PD-1 inhibitor +/- trastuzumab as first-line treatment for
More news about: Curis, Inc.
May 12, 2026, 09:00 ET $4.3 Billion For Antamina's Silver; $469 Million In One Quarter For Royal Gold - The Royalty Companies Continue Expanding
Franco-Nevada has now posted 19 consecutive years of dividend increases. The asset-light model is winning the cycle — and the long-life, large-scale Pd-Au-Pt deposits are exactly what the next round of capital is looking for.Equity
More news about: Equity Insider
May 12, 2026, 07:00 ET Compugen to Participate in 2026 Stifel Virtual Targeted Oncology Forum
evaluating COM701 as a single agent in maintenance therapy in relapsed platinum sensitive ovarian cancer (named MAIA-ovarian trial). Rilvegostomig, a PD-1/TIGIT bispecific antibody with a TIGIT component that is derived from COM902 program, is being developed by AstraZeneca pursuant to an exclusive license
More news about: Compugen Ltd.
May 11, 2026, 09:29 ET Cyient Semiconductors Launches India's First GaN Power IC Family Leveraging Navitas Technology
increase overall system performance.Cyient Semiconductors' initial GaN portfolio targets power applications up to 650 V, including consumer USB‑PD chargers, laptop and mobile adapters; AC‑DC power supplies; AI data center and telecommunications power systems; and e‑mobility charging platforms.Looking
More news about: Cyient
May 11, 2026, 09:29 ET Cyient Semiconductors Launches India's First GaN Power IC Family Leveraging Navitas Technology
increase overall system performance.Cyient Semiconductors' initial GaN portfolio targets power applications up to 650 V, including consumer USB‑PD chargers, laptop and mobile adapters; AC‑DC power supplies; AI data center and telecommunications power systems; and e‑mobility charging platforms.Looking
More news about: Cyient
May 11, 2026, 08:00 ET Inhibrx Reports Interim Phase 2 Data for INBRX-106 in First-Line HNSCC; Initial Results Demonstrate Potential Costimulatory Benefit Over PD-1 Monotherapy
HNSCC was selected as a proof-of-concept indication, as PD-1 monotherapy is active in this tumor type but leaves significant room for improvement. The trial design was modeled after KEYNOTE-048, focusing on patients with high PD-L1 expression (CPS ≥ 20) in order to further sharpen the ability
More news about: Inhibrx Biosciences, Inc.
May 11, 2026, 07:51 ET ProBio and Curocell Achieve Key CAR-T Milestone with BLA Regulatory Approval and Commercial Readiness
thrombocytopenia. A key differentiating feature of CRC01 lies in Curocell's proprietary OVIS™ platform, which suppresses the expression of immune checkpoint receptors PD-1 and TIGIT in CAR-T cells. This innovative mechanism is designed to address immune suppression within the tumor microenvironment, potentially enhancing
More news about: ProBio Inc.
May 11, 2026, 07:00 ET Leads Biolabs R&D Symposium: Platform Synergy and Multi-Mechanism Integration Reshape the Immuno-Oncology Landscape
first-in-class (FIC) PD-L1/4-1BB bispecific antibody—to the BLA (Biologics License Application) submission stage.LBL-024: A Potential IO 2.0 Pan-Tumor Backbone Therapy with Survival Benefit. Utilizing the unique 2:2 molecular structure design of the X-body platform, LBL-024 releases PD-L1-mediated
More news about: Nanjing Leads Biolabs Co., Ltd.
May 10, 2026, 20:00 ET Innovent Announces IBI363 (PD-1/IL-2α-bias Bispecific Fusion Protein) Received Third NMPA Breakthrough Therapy Designation for MSS/pMMR Metastatic Colorectal Cancer
and prognosis remains poor.About IBI363IBI363 is a first-in-class PD-1/IL-2α-bias bispecific fusion protein developed by Innovent Biologics. It functions by both blocking the PD-1/PD-L1 pathway and selectively activating the IL-2 pathway. The IL-2 arm of IBI363 is designed
More news about: Innovent Biologics
May 08, 2026, 16:00 ET Inhibrx To Host Webcast Presentation to Provide Clinical Update on INBRX-106 HexAgon Study in First Line HNSCC
combination with pembrolizumab (the combination arm) versus pembrolizumab monotherapy (the control arm) in first-line patients with treatment-naïve, PD-L1 positive (CPS ≥ 20) metastatic or unresectable recurrent Head and Neck Squamous Cell Carcinoma (HNSCC).
More news about: Inhibrx Biosciences, Inc.
May 08, 2026, 07:12 ET PAN GLOBAL MELDET HOCHGRADIGE GOLDMINERALISIERUNG AN DER OBERFLÄCHE MIT 20,2 G/T ÜBER 5,0 METER BEIM PROJEKT CÁRMENES IN SPANIEN
PtPdNummer
More news about: Pan Global Resources Inc.